Figure 8: BET bromodomain inhibition as a new therapeutic strategy to block the vicious cycle in bone tumours. | Nature Communications

Figure 8: BET bromodomain inhibition as a new therapeutic strategy to block the vicious cycle in bone tumours.

From: Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle

Figure 8

The vicious cycle described in primary bone tumours and bone metastases consists of release of osteolytic mediators by tumour cells and OBs, thus inducing bone degradation and then releasing growth factors from degraded bone, enhancing tumour cell growth and further release of osteolytic mediators. In the present study, we describe for the first time the therapeutic interest of BET bromodomain inhibitor, JQ1, in the treatment of osteosarcoma not only by the prevention of osteosarcoma-induced osteolysis by blocking both OC and OB differentiation, but also by the inhibition of associated tumour development, leading to increased survival rate.

Back to article page